Similar articles for PMID: 19622372

Year	Number of Results
1993	1
1994	1
1998	1
1999	1
2000	1
2001	3
2002	3
2003	2
2004	1
2005	5
2006	13
2007	16
2008	21
2009	66
2010	3
2011	7
2012	5
2013	2
2014	1
2015	2
2016	2
2018	1
2020	2
2022	1
2024	0

1

Novel HCV replication mouse model using human hepatocellular carcinoma xenografts.

Guévin C, Lamarre A, Labonté P. Guévin C, et al. Antiviral Res. 2009 Oct;84(1):14-22. doi: 10.1016/j.antiviral.2009.07.009. Epub 2009 Jul 19. Antiviral Res. 2009. PMID: 19622372

2

Novel robust hepatitis C virus mouse efficacy model.

Zhu Q, Oei Y, Mendel DB, Garrett EN, Patawaran MB, Hollenbach PW, Aukerman SL, Weiner AJ. Zhu Q, et al. Antimicrob Agents Chemother. 2006 Oct;50(10):3260-8. doi: 10.1128/AAC.00413-06. Antimicrob Agents Chemother. 2006. PMID: 17005803 Free PMC article.

3

Hepatitis C virus infection in mouse hepatoma cells co-expressing human CD81 and Sip-L.

Yeh CT, Lai HY, Yeh YJ, Cheng JC. Yeh CT, et al. Biochem Biophys Res Commun. 2008 Jul 18;372(1):157-61. doi: 10.1016/j.bbrc.2008.05.018. Epub 2008 May 12. Biochem Biophys Res Commun. 2008. PMID: 18474223

4

A hepatitis C virus xenograft mouse efficacy model.

Zhu Q, Weiner AJ. Zhu Q, et al. Methods Mol Biol. 2009;511:323-31. doi: 10.1007/978-1-59745-447-6_14. Methods Mol Biol. 2009. PMID: 19347304

5

Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.

Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G. Vanwolleghem T, et al. Gastroenterology. 2007 Oct;133(4):1144-55. doi: 10.1053/j.gastro.2007.07.007. Epub 2007 Jul 10. Gastroenterology. 2007. PMID: 17919490

6

Hepatocellular carcinoma xenograft supports HCV replication: a mouse model for evaluating antivirals.

Hazari S, Hefler HJ, Chandra PK, Poat B, Gunduz F, Ooms T, Wu T, Balart LA, Dash S. Hazari S, et al. World J Gastroenterol. 2011 Jan 21;17(3):300-12. doi: 10.3748/wjg.v17.i3.300. World J Gastroenterol. 2011. PMID: 21253388 Free PMC article.

7

Mouse hepatic cells support assembly of infectious hepatitis C virus particles.

Long G, Hiet MS, Windisch MP, Lee JY, Lohmann V, Bartenschlager R. Long G, et al. Gastroenterology. 2011 Sep;141(3):1057-66. doi: 10.1053/j.gastro.2011.06.010. Epub 2011 Jun 13. Gastroenterology. 2011. PMID: 21699799

8

Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication.

Yu L, Aoki C, Shimizu Y, Shimizu K, Hou W, Yagyu F, Wen X, Oshima M, Iwamoto A, Gao B, Liu W, Gao GF, Kitamura Y. Yu L, et al. J Virol Methods. 2010 Nov;169(2):380-4. doi: 10.1016/j.jviromet.2010.08.009. Epub 2010 Aug 14. J Virol Methods. 2010. PMID: 20713089

9

Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation.

Dash S, Prabhu R, Hazari S, Bastian F, Garry R, Zou W, Haque S, Joshi V, Regenstein FG, Thung SN. Dash S, et al. Liver Int. 2005 Jun;25(3):580-94. doi: 10.1111/j.1478-3231.2005.01082.x. Liver Int. 2005. PMID: 15910496

10

Evaluation systems for anti-HCV drugs.

Moriishi K, Matsuura Y. Moriishi K, et al. Adv Drug Deliv Rev. 2007 Oct 10;59(12):1213-21. doi: 10.1016/j.addr.2007.04.015. Epub 2007 Aug 9. Adv Drug Deliv Rev. 2007. PMID: 17720275 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

154 results

Results by year